Clinical practice guideline for the prevention, diagnosis, and treatment of glucocorticoid-induced osteoporosis. Colombian Association of Rheumatology, 2023
Monique Chalem , Noemi Casas , Aura María Domínguez , Daniel Gerardo Fernández , Andrés González , Edwin Jáuregui , José Fernando Molina , Diana Nathalie Rincón , Carlos Enrique Toro-Gutiérrez , Francisco Juan Vargas Grajales , Susan Martínez , Linda Ibatá
{"title":"Clinical practice guideline for the prevention, diagnosis, and treatment of glucocorticoid-induced osteoporosis. Colombian Association of Rheumatology, 2023","authors":"Monique Chalem , Noemi Casas , Aura María Domínguez , Daniel Gerardo Fernández , Andrés González , Edwin Jáuregui , José Fernando Molina , Diana Nathalie Rincón , Carlos Enrique Toro-Gutiérrez , Francisco Juan Vargas Grajales , Susan Martínez , Linda Ibatá","doi":"10.1016/j.rcreue.2024.07.005","DOIUrl":null,"url":null,"abstract":"<div><p>The use of glucocorticoids is the most frequent cause of osteoporosis and osteoporotic fractures. Considering that glucocorticoid-induced osteoporosis (GIOP) is an underestimated and generally untreated problem, the Bone Metabolism study group of the Colombian Association of Rheumatology decided to create this Clinical Practice Guideline (CPG) in order to support rheumatologists and other specialists in the country who use this type of medication to manage inflammatory and autoimmune conditions, with recommendations on prevention, diagnosis, and treatment of GIOP. The recommendations presented here were constructed following the GRADE-ADOLOPMENT methodology. The American College of Rheumatology guideline, Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis, was selected as the source for updating the literature searches. The development of this CPG also included the participation of clinical experts from different specialties, patients, and the EpiThink Health Consulting technical-methodological team.</p></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"31 3","pages":"Pages 365-379"},"PeriodicalIF":0.0000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Colombiana de Reumatología (English Edition)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2444440524001110","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The use of glucocorticoids is the most frequent cause of osteoporosis and osteoporotic fractures. Considering that glucocorticoid-induced osteoporosis (GIOP) is an underestimated and generally untreated problem, the Bone Metabolism study group of the Colombian Association of Rheumatology decided to create this Clinical Practice Guideline (CPG) in order to support rheumatologists and other specialists in the country who use this type of medication to manage inflammatory and autoimmune conditions, with recommendations on prevention, diagnosis, and treatment of GIOP. The recommendations presented here were constructed following the GRADE-ADOLOPMENT methodology. The American College of Rheumatology guideline, Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis, was selected as the source for updating the literature searches. The development of this CPG also included the participation of clinical experts from different specialties, patients, and the EpiThink Health Consulting technical-methodological team.